News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antibe Therapeutics Inc. Announces Submission Of Clinical Trial Application To Health Canada For ATB-346


5/21/2014 9:48:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSXV:ATE) is pleased to announce the submission of a Clinical Trial Application (“CTA”) to Health Canada for its lead drug, ATB-346. The CTA proposes the initiation of a clinical study entitled “A Double-Blind, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single/Multiple Ascending Doses of ATB-346 Orally Administered in Healthy Male and Female Subjects.” The submission represents a significant milestone on a well-defined pathway for the development of ATB-346.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES